The article offers the outlines of the Brazilian biotechnology in human health sector  in terms of scientific output  dependence of the private sector on public funding for R  the low capacity for innovation in the development of new pharmaceuticals and the uncoupling between progresses in science and technology and innovation in the private sector of biotechnology in human health  showing its spatial and sectoral concentration  Looking at three relevant aspects   territorial distribution  scientific output and R in private corporations   it indicates that  despite the progresses in the sector  there are still weaknesses to overcome in order to promote economic growth based on knowledge and innovation 